The biosimilars market has expanded rapidly over the past decade, and for good reason. These medicines have brought meaningful cost savings and widened patient access to biologics for conditions like rheumatoid arthritis, Crohn’s disease, and several cancers. The global biosimilars market is projected to exceed $60 billion by 2030, driven largely by patent expirations of blockbuster originators like adalimumab, trastuzumab, and bevacizumab.

But here is where many professionals, and even some regulators, slip into a familiar assumption: biosimilars are approved as “highly similar” to their reference products, so the safety story should be straightforward, much like generic small-molecule drugs.

It is not.

This is the question worth sitting with: generics are essentially identical chemical copies, so why does switching to a biosimilar demand genuinely heightened pharmacovigilance? The answer lies in the nature of what biosimilars are, how they are made, and what that means once millions of patients are using them across diverse real-world conditions.

---

Not All “Similar” Is Equal: The Manufacturing Reality

A generic tablet of metformin contains the same molecule as its originator, atom for atom. You can synthesize it in a lab and confirm identity with a few standard analytical tests. A biosimilar monoclonal antibody or erythropoietin is a different matter entirely.

Biosimilars are large, structurally complex proteins produced in living cell systems, whether bacterial, yeast, or mammalian cell lines. The originator molecule and the biosimilar share the same amino acid sequence and the same intended biological function, but the production process, the cell line used, the fermentation conditions, the purification steps, and the scale-up decisions can all introduce minor differences in post-translational modifications, glycosylation patterns, aggregation profiles, and impurity levels.

The regulatory standard of “highly similar with no clinically meaningful differences” is rigorous and scientifically sound. But it is not the same as identical. And in pharmacovigilance terms, that distinction carries weight.

Manufacturing drift is a known phenomenon even within the originator product. A manufacturer’s process evolves over time, and the molecule that patients receive today may differ slightly from what was on the market ten years ago. Biosimilars introduce additional layers: multiple manufacturers referencing the same originator, each with their own proprietary process, scaling their production independently, and launching in overlapping markets. The post-marketing surveillance environment becomes considerably more complex than it is for small-molecule generics, where the core safety profile of a well-established chemical entity changes very little between brands.

---

The Traceability Problem

Ask a pharmacovigilance professional what keeps them awake in the biosimilars space, and traceability will come up quickly.

When a patient develops an unexpected adverse event or a provider suspects a loss of efficacy, the first question is: which product, exactly, did that patient receive? For conventional drugs, brand name alone usually suffices. For biosimilars, you need the brand name, the batch or lot number, and ideally the route of administration and device used. That information is frequently absent from spontaneous adverse event reports.

The reason this matters so much is attribution. Multiple biosimilars may reference the same originator. If an immunogenicity signal emerges, regulators and manufacturers need to know whether it is product-specific, batch-specific, or a class effect. Without complete traceability data, distinguishing signal from noise becomes genuinely difficult, and the consequences of getting it wrong run in both directions: a real safety issue goes undetected, or a safe product gets unfairly implicated.

The FDA addressed part of this problem by requiring nonproprietary names with distinguishable suffixes for biological products in the United States, for example filgrastim-aafi or infliximab-dyyb. The EMA takes a different approach, relying on brand name and batch documentation rather than modified INN. Neither system is perfect in practice. In India, which is both a major biosimilar manufacturer and a growing market, regulatory traceability requirements are still maturing, making this a particularly relevant challenge for local pharmacovigilance teams.

The practical implication for anyone receiving or reviewing safety reports: capturing brand name and batch number is not optional. It should be treated as a minimum reporting standard for all biological products, biosimilars included.

---

Cold Chains, Devices, and Real-World Handling

Small-molecule generics are generally robust. A tablet that sits in a warm warehouse for a few extra days does not become a different medicine. Biosimilars are not that forgiving.

These products require strict cold chain maintenance throughout the supply and distribution process. Many are delivered via specialized devices, prefilled syringes, autoinjectors, or on-body injectors, each with its own design and handling requirements. Degradation due to temperature excursions or mechanical stress does not always produce an obviously spoiled product. What it can produce is reduced efficacy, aggregated protein, or an altered immunogenicity profile. Patients and providers may interpret this as treatment failure or an adverse reaction, neither of which gets correctly attributed to handling in a routine spontaneous report.

Pharmacovigilance for biosimilars therefore has to extend beyond the drug itself. Signal detection systems need to account for cold chain failures, device malfunctions, and real-world administration errors as plausible contributors to reported events. This requires active collaboration between pharmacovigilance teams, supply chain functions, and device manufacturers, a level of coordination that the generic drug world rarely demands.

---

Abbreviated Development, Amplified Post-Market Responsibility

Biosimilar clinical development programmes are intentionally smaller than those required for originators. The regulatory logic is sound: you are not establishing safety and efficacy from scratch, you are demonstrating comparability to a product whose profile is already well-characterised. Equivalence and non-inferiority designs are used, with targeted immunogenicity and efficacy endpoints.

The consequence is that rare adverse events, those occurring at a frequency of 1 in 10,000 or lower, may not appear in pre-approval trials simply because the patient numbers are insufficient to detect them. The same applies to long-term outcomes. Post-approval surveillance is where that gap gets filled, and for biosimilars the stakes are high because immunogenicity, in particular, can develop over months or years of treatment.

Anti-drug antibody formation is a defining concern. Neutralising antibodies can eliminate a product’s efficacy or, in serious cases, cause cross-reactive loss of function affecting endogenous proteins. This was famously documented with Eprex-associated pure red cell aplasia in the early 2000s, an event linked to a formulation change in the originator erythropoietin. It remains one of the most cited examples of why biologics pharmacovigilance cannot be passive.

Post-authorisation safety studies and post-authorisation efficacy studies are mandatory for most biosimilars approved through the EMA’s centralised procedure. Real-world evidence drawn from registries, electronic health records, and insurance claims databases is increasingly expected to complement spontaneous reporting, particularly for immunogenicity outcomes and switching studies.

---

Switching, Interchangeability, and Nocebo

The clinical and regulatory question of whether a biosimilar can be substituted for its reference product, or interchanged at the pharmacy level without prescriber intervention, is actively debated in most markets. From a pharmacovigilance perspective, switching introduces specific challenges.

A patient who has received the originator product for two years and then transitions to a biosimilar brings a complex immunological history to the new exposure. Multiple sequential switches, from originator to biosimilar A to biosimilar B, compound that complexity and make adverse event attribution genuinely difficult. Registries designed to track switching outcomes are valuable precisely because they capture this longitudinal exposure context that spontaneous reporting systems cannot.

Nocebo effects are also real and should not be dismissed as anecdotal. Patients who are anxious about switching, or who have been inadequately counselled, may report worsening symptoms that are not pharmacologically attributable to the new product. Distinguishing nocebo from a genuine pharmacological difference requires both careful reporting and investment in patient and prescriber education. This is not purely a clinical responsibility; it sits squarely within the pharmacovigilance ecosystem.

---

What Good Biosimilars Pharmacovigilance Actually Looks Like

The regulatory frameworks are in place. EMA requires Risk Management Plans for all biosimilars. FDA mandates post-marketing safety commitments comparable to reference biologics. The gap is in consistent implementation, particularly in lower-resource settings and in markets where biosimilar adoption is accelerating faster than local PV infrastructure can keep pace.

Several practices distinguish mature biosimilar pharmacovigilance programmes from those that are merely compliant on paper.

Reporting quality has to be prioritised from the first prescription. Healthcare providers need to be trained not just on the clinical use of biosimilars but specifically on what to capture in an adverse event report: the brand name, batch number, device used, prior biologic exposure, and any storage or handling issues. This information is routinely missing from spontaneous reports and its absence directly impairs signal detection.

Signal detection needs to be configured for the biologics context. Grouping adverse events purely by active substance, without distinguishing between products, will mask product-specific signals. Conversely, fragmenting data too finely across small product populations will suppress signals that should be detected at the class level. Both errors have occurred in practice.

Real-world evidence, from registries like the European biologics registers in rheumatology or biosimilar-specific pharmacovigilance databases, provides the longitudinal data that spontaneous reporting cannot. Investment in registry infrastructure, particularly in markets like India where biosimilar penetration is growing and local patient populations have distinct characteristics, is a genuine public health priority.

Cold chain audits, device incident tracking, and supply chain integration into PV workflows are still exceptions rather than norms in most organisations. They should not be.

---

The Road Ahead

The challenges in biosimilars pharmacovigilance are real, but they are not intractable. Underreporting remains the most persistent problem, followed by incomplete batch data and the absence of harmonised global traceability standards. These are structural issues that require regulatory will and industry commitment to fix.

The opportunities are equally clear. AI-assisted signal detection tools are improving the ability to identify patterns across large, noisy datasets. Electronic health record integration is reducing the manual burden of pharmacovigilance data collection. Better international harmonisation of naming conventions and reporting requirements would reduce the inconsistencies that currently allow the same product to be tracked differently across markets.

The stakes justify the investment. Biosimilars have the potential to generate hundreds of billions in savings globally over the next decade, and to extend access to life-changing therapies to patients who cannot currently afford their originators. That potential is only fully realised if post-market surveillance is rigorous enough to catch real problems early, and transparent enough to sustain public and prescriber confidence in these products.

Pharmacovigilance does not just protect patients after approval. In the biosimilars context, it is part of what makes broader adoption viable in the first place. Strong surveillance is not a regulatory checkbox. It is the mechanism through which trust in these medicines is earned and maintained.

For professionals working in this space, whether in PV operations, regulatory affairs, medical affairs, or clinical practice, the ask is straightforward: report completely, report accurately, and treat every adverse event in a biologic patient as an opportunity to build the evidence base that the field still needs.